kidney
Advertisement
Ajay Singh discusses the state of rare kidney disease research.
Dietitian Lauren Budd Levy explains the importance of renal nutrition and related sessions at NKF SKM25.
LaVarne Burton of the American Kidney Fund opened Kidney Action Week 2025 with welcome remarks on March 3.
Listen to the discussion of Chapter 17 of Dr. Burton Rose's book, focused on simple and mixed acid-base disorders.
Travere will submit an application to the FDA requesting approval of sparsentan for focal segmental glomerulosclerosis.
How accurately and efficiently does artificial intelligence perform clinical prescreening compared with nephrologists?
The WRAPSODY stent may help restore circuit patency when stenosis or occlusion occurs within the AVG or AVF for hemodialysis.
Listen to part 2 of the discussion of Chapter 16 of Dr. Burton Rose's book, focused on edematous states.
A MAMS platform trial will examine use of antiproteinuric and immunomodulatory therapies in glomerular diseases.
A clinical trial examined the relationship between steroid exposure and bone mineral density changes in children.
The American Kidney Fund will host Kidney Action Week, a week of free, virtual sessions about kidney health, March 3-7, 2025.
The American Kidney Fund has named Pranav Garimella as its first chief medical officer.
Evergreen Nephrology has raised $130 million in capital to expand its value-based care model for kidney disease.
Listen to the discussion of Chapter 16 of Dr. Burton Rose's book, focused on edematous states.
A global review noted changes in kidney care delivery but revealed gaps in access to kidney replacement therapies.
Effects of SGLT2 inhibitors on renal outcomes in patients with CKD, heart failure, and type 2 diabetes were examined.
Researchers evaluated the efficacy of sparsentan in a subset of patients with genetic focal segmental glomerulosclerosis.
Len Usvyat spoke with Nephrology Times about the use of artificial intelligence in kidney care.
The Filtrate rerecorded their episode on the PRAECIS trial regarding a blood test for preeclampsia due to listener feedback.
Finerenone did not modify kidney outcomes but reduced albuminuria and risk of new-onset macroalbuminuria in patients with HF.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.